Page last updated: 2024-12-06

nebracetam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nebracetam is a racetam drug with nootropic properties. It is a synthetic analog of piracetam, and its chemical structure is similar to that of piracetam, but with an additional N-methyl group on the pyrrolidone ring. Nebracetam has been shown to improve cognitive function in animal models, particularly in tasks involving learning and memory. It is thought to work by modulating the activity of neurotransmitters like acetylcholine and glutamate, as well as by promoting neuroplasticity. However, research on nebracetam in humans is limited, and its clinical efficacy remains unclear. It is currently being investigated for its potential therapeutic benefits in treating cognitive decline associated with aging and neurological disorders.'

nebracetam: RN given refers to parent cpd; agonist for muscarinic receptors [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65926
CHEMBL ID2104682
SCHEMBL ID195354
MeSH IDM0158836

Synonyms (34)

Synonym
AC-5598
97205-34-0
nebracetam
4-aminomethyl-1-benzylpyrrolidine-2-one
2-pyrrolidinone, 4-(aminomethyl)-1-(phenylmethyl)-
4-(aminomethyl)-1-benzylpyrrolidin-2-one
L001348
AKOS005066167
t30038qi8n ,
dl-nebracetam
unii-t30038qi8n
nebracetam [inn]
CHEMBL2104682
4-(aminomethyl)-1-benzyl-pyrrolidin-2-one
nebracetam [mi]
(+/-)-4-(aminomethyl)-1-benzyl-2-pyrrolidinone
nebracetam [mart.]
SCHEMBL195354
MB01547
J-500040
(+)-4-(aminomethyl)-1-(benzyl)-pyrrolidin-2-one
1-benzyl-4-aminomethyl-pyrrolidin-2-one
LCAFGJGYCUMTGS-UHFFFAOYSA-N
4-aminomethyl-1-benzylpyrrolidin-2-one
116041-13-5
SR-01000945271-1
sr-01000945271
Q6984655
nebracetam (free base)
web 1881 fu (free base)
EN300-118105
FT-0777810
(+/-)-nebracetam
DTXSID00869598

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Pretreatment of nebracetam at 1 mM or pentobarbital at 0.1 mM attenuated a decline of 2DG uptake and CA1 field potentials under the condition of ischemia."( Neuroprotective effect of WEB 1881 FU (nebracetam) on an ischemia-induced deficit of glucose uptake in rat hippocampal and cerebral cortical slices and CA1 field potential in hippocampal slices.
Kagami-ishi, Y; Shibata, S; Ueki, S; Watanabe, S, 1992
)
0.89
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (9.52)18.7374
1990's19 (90.48)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.27 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index5.38 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (7.41%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (92.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]